Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 10.4% - Time to Buy?

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) shares were up 10.4% during mid-day trading on Tuesday . The company traded as high as $7.13 and last traded at $7.36. Approximately 1,290,921 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 1,683,123 shares. The stock had previously closed at $6.67.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Scotiabank upped their price target on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. The Goldman Sachs Group raised their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $11.00 price objective (up previously from $7.00) on shares of Adaptive Biotechnologies in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.10.

Adaptive Biotechnologies Stock Up 12.3 %

The firm has a 50-day moving average of $7.56 and a 200 day moving average of $6.06. The stock has a market capitalization of $1.11 billion, a P/E ratio of -6.87 and a beta of 1.53.

Remove Ads

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same quarter in the prior year, the business posted ($0.30) earnings per share. Analysts predict that Adaptive Biotechnologies Co. will post -0.92 EPS for the current fiscal year.

Insider Activity

In other news, CEO Chad M. Robins sold 211,160 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $8.50, for a total value of $1,794,860.00. Following the sale, the chief executive officer now owns 2,576,701 shares of the company's stock, valued at approximately $21,901,958.50. This represents a 7.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kyle Piskel sold 10,320 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total transaction of $72,033.60. Following the transaction, the chief financial officer now directly owns 269,010 shares of the company's stock, valued at $1,877,689.80. This represents a 3.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 692,903 shares of company stock worth $5,552,572. Company insiders own 6.20% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ADPT. Barclays PLC raised its position in Adaptive Biotechnologies by 149.5% in the 3rd quarter. Barclays PLC now owns 230,177 shares of the company's stock valued at $1,180,000 after purchasing an additional 137,936 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Adaptive Biotechnologies by 12.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company's stock valued at $39,597,000 after buying an additional 834,253 shares during the last quarter. Millrace Asset Group Inc. acquired a new position in Adaptive Biotechnologies during the 3rd quarter worth about $1,396,000. Point72 Asset Management L.P. bought a new stake in Adaptive Biotechnologies during the 3rd quarter worth about $2,537,000. Finally, Rubric Capital Management LP increased its position in Adaptive Biotechnologies by 2.9% in the 3rd quarter. Rubric Capital Management LP now owns 14,400,000 shares of the company's stock valued at $73,728,000 after acquiring an additional 400,000 shares in the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.